Amgen Inc 'with Epogen was the first blockbuster biotech drugs. Epogen help prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease and death. While market Epogen, which included dialysis patients and those with cancer undergoing chemotherapy, is estimated at $ 1 billion opportunity. After a critical breakthrough that allowed Amgen, to identify the EPO gene, the company has applied for a number of patents to protect its achievements. However, to my surprise, I found out that Amgen EPO has been patented. Institute of Genetics, the holder of a patent cross-license grant requested. Manager Amgen, needed to decide how best to compete with a rival. "Hide
by Felix Oberholzer-Gee, Dennis Yao Source: Harvard Business School 7 pages. Publication Date: December 14, 2005. Prod. #: 706454-PDF-ENG
Related Case Solutions & Analyses:
Bank of America: Mobile Banking (Abridged)
Financial System Security: Harshad Mehta and the Billion-Dollar Scam
Progressive Corp.
Wintel (F): From Multi-Geographic Contact to Open Source
Bangkoks Second Stage Expressway
Trilogy Health Services, LLC: Building a Great Service Company
FINANCING THE MOZAL PROJECT
WLR Foods and Tyson Foods
Goldman Sachs: Anchoring Standards after the Financial Crises
Financial Market
